Itay Shalev, Kit Man Wong, Katharina Foerster, Yi Zhu, Cecilia Chan, Asif Maknojia, Jianhua Zhang, Xue‐Zhong Ma, Xiao Chun Yang, Julia Fang Gao, Hao Liu, Nazia Selzner, David A. Clark, Oyedele Adeyi, M. James Phillips, Reginald R. Gorczynski, David Grant, Ian McGilvray, Gary Levy – 28 January 2009 – Fulminant viral hepatitis (FH) remains an important clinical problem in which the underlying pathogenesis is not well understood.

Jasmin T. Ney, Thomas Schmidt, Christian Kurts, Qi Zhou, Dawid Eckert, Dean W. Felsher, Hubert Schorle, Percy Knolle, Thomas Tüting, Winfried Barchet, Reinhard Büttner, Andreas Limmer, Ines Gütgemann – 28 January 2009 – The reason the adaptive immune system fails in advanced liver tumors is largely unclear. To address this question, we have developed a novel murine model that combines c‐myc–induced autochthonous tumorigenesis with expression of a cognate antigen, ovalbumin (OVA).

Ivo W. Graziadei, Wolfgang Vogel – 28 January 2009

Mercedes Vázquez‐Chantada, Usue Ariz, Marta Varela‐Rey, Nieves Embade, Nuria Martínez‐Lopez, David Fernández‐Ramos, Laura Gómez‐Santos, Santiago Lamas, Shelly C. Lu, M. Luz Martínez‐Chantar, José M. Mato – 28 January 2009 – S‐adenosylmethionine (SAMe) is involved in numerous complex hepatic processes such as hepatocyte proliferation, death, inflammatory responses, and antioxidant defense. One of the most relevant actions of SAMe is the inhibition of hepatocyte proliferation during liver regeneration.

Rong‐Ze Yang, Soohyun Park, William J. Reagan, Rick Goldstein, Shao Zhong, Michael Lawton, Francis Rajamohan, Kun Qian, Li Liu, Da‐Wei Gong – 28 January 2009 – The elevation of serum alanine aminotransferase (ALT) is regarded as an indicator of liver damage based on the presumption that ALT protein is specifically and abundantly expressed in the liver. However, ALT elevation is also observed in non–liver injury conditions (for example, muscle injury) and in apparently healthy people.

Keith D. Lindor – 28 January 2009

Grant A. Ramm, Ross W. Shepherd, Anita C. Hoskins, Sonia A. Greco, Agnieszka D. Ney, Tamara N. Pereira, Kim R. Bridle, James D. Doecke, Peter J. Meikle, Bruno Turlin, Peter J. Lewindon – 28 January 2009 – Cholestatic liver diseases, such as cystic fibrosis (CF) liver disease and biliary atresia, predominate as causes of childhood cirrhosis. Despite diverse etiologies, the stereotypic final pathway involves fibrogenesis where hepatic stellate cells (HSCs) are recruited, producing excess collagen which initiates biliary fibrosis.

Chung‐Mau Lo – 28 January 2009

Federico Aucejo, Richard Kim, Nizar Zein, Cristiano Quintini, Teresa Diago Uso, Rocio Lopez, Bijan Eghtesad, John Fung, Charles Miller, Lisa Yerian – 28 January 2009 – Hepatocellular carcinoma (HCC) is a highly vascular tumor. Angiogenesis in HCC is mediated at least in part by vascular endothelial growth factor (VEGF), which is expressed in HCC and surrounding cirrhotic tissue.

Björn Nashan, Faouzi Saliba, Francois Durand, Rafael Barcéna, Jose Ignacio Herrero, Gilles Mentha, Peter Neuhaus, Matthew Bowles, David Patch, Angel Bernardos, Jürgen Klempnauer, René Bouw, Jane Ives, Richard Mamelok, Diane McKay, Matt Truman, Paul Marotta – 28 January 2009 – The pharmacokinetics of mycophenolate mofetil (MMF) in liver transplant recipients may change because of pharmacokinetic interactions with coadministered immunosuppressants or because changes in the enterohepatic anatomy may affect biotransformation of MMF to mycophenolic acid (MPA) and enterohepatic recirculation of M